Skip to main content
. Author manuscript; available in PMC: 2011 Jun 1.
Published in final edited form as: Oncol Rep. 2011 Feb 24;25(5):1329–1335. doi: 10.3892/or.2011.1195

Figure 2.

Figure 2

TAPI-2, as an ADAM17 activity inhibitor, inhibits TGF-β1-induced glioma cells migration. (A) Confluent T98G glioblastoma cell monoplayers were scratched with a pipette tip and then treated with TGF-β1 (1ng/ml) in the presence or absence of TAPI-2 (Peptides International, Louisville, KY, USA) (100nmol/ml) for 24 h. Cell migration to the wound area was then examined by light microscope for 24h post-scratch. (B) The percentage of total area covered by cells was assessed with MCID software. *P<0.01, compared with control group. (C) T98G glioma cells were seeded onto the upper BD BioCoat matrigel invasion chamber in serum-free medium containing TGF-β1 (1ng/ml) in the presence or absence of TAPI-2 (100nmol/ml). After 24 h of incubation, cells on the lower surface of the membrane were stained with CellTracker Green (Molecular Probes, Eugene, OR), and (D) 9 different areas of invaded cells were counted by a fluorescent microscope. *P<0.01, compared with control group.